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Figure 1. Immune proﬁles of healthy controls and GVHD patients.
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CGVHD develops in more than 50% of survivors of allogeneic
stem cell transplantation and is responsible for mortality in
one third of patients. Long-term immunosuppressive ther-
apy with steroids is the standard treatment. ECP is successful
in about 50% of the patients after 3e 6 months of therapy. To
deﬁnemarkers that might predict successful ECP therapy, we
performed an immunological assessment of 22 patients with
cGVHD prior to initiating ECP. In addition, a comprehensive
assessment of organ system involvement using NIH
Consensus response assessment tools was done at study
entry and at six months. Eighteen patients completed the
study with improvement of GvHD symptoms observed in
eleven patients; seven patients failed to respond to therapy.
PBMCs from leukopheresed blood were obtained prior to the
onset of ECP therapy. Patients who responded to ECP therapy
consistently had a lower CD4/CD8 ratio than non-responders
(0.80  0.64 vs. 3.7  3.1, p < 0.01). The percentages of CD4+
and CD8+ T cells that expressed CD25, CD45RA, or FoxP3
were not different between the two groups. Within the B cell
populations, the phenotype of CD21-CD24+ cells varied be-
tween responders and non-responders with fewer cells
expressing IgD in the responders than in the non-re-
sponders; 61%  19% of CD21-CD24+ B cells were IgD+CD27-
in patient who responded to ECP, as compared to 80%  10%
in patients who did not respond to ECP, p< 0.05. The identity
of these cells is not known, but they may represent a mem-
ory B cell compartment. In addition to obtaining PBMCs prior
to ECP, cells were also obtained at 2, 4, and 6months after theonset of ECP to deﬁne parameters that might track the re-
covery of GvHD. The percentage of CD3-CD20- cells that were
CD34+ cells increased in patients responding to ECP, but
decreased in patients not responding to ECP. The results of
our pilot study suggested that the lymphocyte phenotype
might be a useful predictive marker for successful ECP
therapy. In addition, changes in the CD34+ population might
provide an objective marker for ECP responsiveness.411
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Background: Proteinuria after allogeneic hematopoietic cell
transplantation (allo-HCT) can be multifactorial. Renal
dysfunction and ESRD are more frequent after allo-HCT but
the reports of chronic graft versus host disease affecting the
kidney are rare.
Methods: We report the clinical and natural history of 7
patients presenting with nephrotic range proteinuria (NRP)
deﬁned as >¼3g/24hrs after allo-HCT.
Results:Median age at transplant was 50 years (range 42-58)
years. Four of seven patients had well matched unrelated
donor and three had fully matched sibling grafts (all blood
stem cells, PBSC). The development of NRP was a late event
occurring at a median of +682 d of allo-HSCT (range 342-
880days). All but one of seven patients had evidence of other
chronic GVHD at the time of diagnosis of NRP. Median serum
creatinine at diagnosis was 1.17mg/dl.
Renal biopsy was performed in all cases. Histologic pat-
terns were variable with membranous glomerulonephritis
(n¼4); minimal change disease (n¼1), focal segmental glo-
merulosclerosis (n¼1) and tubulitis (n¼1) observed. At the
onset of NRP 3 out of 7 patients were off all immunosup-
pressants and four were still on tapering doses of immuno-
suppression. Indication for allo-HCT was AML (n¼3), CLL
(n¼2), Multiple myeloma (n¼1) and MDS (n¼1) and in all
cases in remission at the time NRP diagnosis.
Case
number
Proteinuria
g/d
S creat at
diagnosis,
mg/dl
cGVHD
yes/no
Biopsy
result
Treatment Rx
result
1 10.20 0.98 Yes MGN PDN,Tacro,
MMF
CR
2 1.67 1.17 No MGN PDN,Tacro CR
3 5.02 1.26 Yes MCD PDN,Tacro CR
4 2.04 2.96 Yes Tubulitis PDN CR
5 8.48 0.89 Yes MGN PDN,Tacro,
Siro
NR
6 1.57 2.6 Yes MGN PDN,MMF NR
7 0.61 0.8 Yes FSGS PDN,CsA CR
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sone (>0.5mg/kg) but only one had complete remission
with single agent prednisone. Other immunosuppressant
including Rituximab, Tacrolimus, Sirolimus, Cyclosporine,
MMF and Rituxan were used for non-responders to predni-
sone. Time and response to resolution to proteinuria was
variable as shown in the table below. No patients progressed
to ESRD and two patients had died as of the last follow up.
Conclusions: Our data conﬁrm the association of NRP with
chronic GVHD. Monitoring for proteinuria and timely
recognition of this entity may avoid the need for sustained
immunosuppression and nephronal loss.412
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Introduction: In the last two decades, there have been
multiple reasons for the improved outcomes of patients
undergoing allogeneic HSCT including more precise HLA
matching, the advent of reduced intensity conditioning
regimens, use of novel antimicrobial agents, increased op-
tions for immunosuppression and better patient selection.
However, the collective impact of these advances on out-
comes of patients who develop grade III or IV acute GVHD
remains unclear.
Methods: We performed a retrospective analysis of 428
patients with grade III or IV acute GVHD treated at Massa-
chusetts General Hospital and Dana-Farber Cancer Institute
from 1997-2012. We compared overall survival (OS), pro-
gression-free survival (PFS) from underlying disease, and
GVHD-related mortality (GRM) in 3 cohorts based on the
year of transplantation: 1997-2001 (n¼111), 2002-2006
(n¼112), and 2007-2012 (n¼205) using multivariate analysis
adjusting for age, diagnosis, disease status at transplant,
grade of acute GVHD, performance status, comorbidities,
conditioning intensity, HLA match, donor source, and donor-
patient gender match.Results: The most recent cohort of patients with grade III or
IV acute GVHD (2007-2012) was signiﬁcantly older (31%> 60
in 2007-2012, 12% > 60 in 2002-2006, and 4% > 60 in 1997-
2001, p < 0.001), and had lower proportion (35%) of grade IV
acute GVHD compared to earlier cohorts (52% in 1997-2001,
and 38% in 2002-2006, p¼ 0.01). The use of reduced intensity
conditioning, unrelated donors, and peripheral blood stem
cells among patients with grade III-IV acute GVHD increased
over time. In the unadjusted analysis, 12-month OS increased
over time (28% in 1997-2001, 35% in 2002-2006, 48% in
2007-2012, P ¼ 0.004) reﬂecting a decrease in 12-month
GRM (54% in 1997-2001, 51% in 2002-2006, 31% in 2007-
2012, P¼ 0.0001) and improvement in 12-month PFS (27% in
1997-2001, 30% in 2002-2006, 42% in 2007-2012, p ¼ 0.02).
After multivariate analysis, the period of transplantation
remained a strong predictor for OS, and the hazard ratio
(HRs) in 1997-2001 and 2002-2006 compared with 2007-
2012 were 1.55 (95% CI, 1.0-2.3, p ¼ 0.03), and 1.54 (95% CI,
1.2-2.1, p¼ 0.004), respectively. Similarly, more recent period
of transplantation remained a signiﬁcant predictor for lower
GRM [HRs in 1997-2001 and 2002-2006 compared with
2007-2012 were 1.65 (95% CI, 1.0-2.6, p¼0.04), and 2.28 (95%
CI 1.6-3.3, p < 0.001)] and longer PFS [HRs in 1997-2001 and
2002-2006 compared with 2007-2012 were 1.5 (95% CI, 1.0-
2.2, p ¼ 0.04), and 1.49 (95% CI 1.1-2.0, p ¼ 0.007)].
Conclusion: The outcomes of patients who develop grade III
or IV acute GVHD after allogeneic HSCT has improved over
time with lower GRM and improvement in PFS and OS. Our
results suggest that the multiple innovations in trans-
plantation care have led to improved outcomes in patients
with grade III and IV acute GVHD, and outcomes are not as
poor as historically reported.413
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The 2005 NIH chronic GVHD organ and overall clinical
severity score is based on the assessment of current status
regardless of whether abnormalities are caused by chronic
GVHD or other conditions. The score assignment does not
require knowledge of past manifestations, attribution, or
whether GVHD is still active; it simply describes the patient’s
current condition. The aim of this prospective study was to
analyze confounding factors affecting organ-speciﬁc 0-3
scores and global severity scores in patients with chronic
GVHD.
Patients and Methods: All 139 patients with NIH chronic
GVHD evaluated at our center between January and
September 2013 were included in this study. Medical pro-
viders completed the NIH 0-3 organ-speciﬁc scoring form
with two additional questions for each organ to identify
abnormalities that were 1) not attributed to chronic GVHD
(yes/no), or 2) attributed to chronic GVHD plus other causes
(yes/no). Causes of abnormalities attributed to causes other
than GVHD were described by the medical evaluator.
Results: Sixty-nine (50%) of the 139 patients had abnor-
malities attributed only to chronic GVHD. Fifty-nine (42%)
patients had abnormalities not attributed to chronic GVHD in
at least 1 organ, and 24 (17%) had abnormalities attributed to
chronic GVHD plus other causes in at least 1 organ. The
distribution of organ involvement according to attribution of
